Company profile for Yuhan Corporation

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

After returning from the USA in 1925, Dr. Ilhan New witnessed the hardship in his country under Japanese imperialism. He founded the Yuhan corporation in 1926 with the belief that only healthy people could reclaim their sovereignty and he sought to solve widespread public health problems. Over 80 years, the founding creed to make the best medicines and contribute to public health has been succeeded by us through our intense re...
After returning from the USA in 1925, Dr. Ilhan New witnessed the hardship in his country under Japanese imperialism. He founded the Yuhan corporation in 1926 with the belief that only healthy people could reclaim their sovereignty and he sought to solve widespread public health problems. Over 80 years, the founding creed to make the best medicines and contribute to public health has been succeeded by us through our intense research and development activities and successful collaboration with multinational pharmaceutical companies. As a result, Yuhan is one of the most respected companies in Korea for 20 consecutive years, according to the annual Korean Management Association Consulting (KMAC) survey. Yuhan has been playing active role in global citizenship since its foundation in 1926. Even before global citizenship was conceptualized, Dr. New believed that was the duty and responsibility of business to develop itself for the prosperity of all society, and his own personal commitment to this was the donation of all of his personal property throughout his life up until his death. Yuhan is continuously making its social contribution by establishing a system where part of the company’s profits is returned to society. This endeavor has been domestically and internationally recognized through various organizations and publications. Yuhan has always emphasized research and development as its top corporate priority. The company approaches R&D through innovative, nimble and translational methodologies. This three-fold dynamic allows Yuhan to continue its over-arching commitment to enhancing quality of life. True to the company’s founding mission, Yuhan focuses its R&D efforts on developing the kinds of products people need most. By developing therapies for treating inflammatory, autoimmune, oncologic and metabolic diseases, Yuhan has significantly advanced the science and understanding of these prevalent disease processes. This rich body of knowledge and wealth of experience positions Yuhan on the cutting edge for developing unique, innovative, finished products and to partnering successfully with other developers. Yuhan has been playing active role in global citizenship since its foundation in 1926. Even before global citizenship was conceptualized, Dr. New believed that was the duty and responsibility of business to develop itself for the prosperity of all society, and his own personal commitment to this was the donation of all of his personal property throughout his life up until his death. Yuhan is continuously making its social contribution by establishing a system where part of the company’s profits is returned to society. This endeavor has been domestically and internationally recognized through various organizations and publications. The R&D Priority Yuhan has always emphasized research and development as its top corporate priority. The company approaches R&D through innovative, nimble and translational methodologies. This three-fold dynamic allows Yuhan to continue its over-arching commitment to enhancing quality of life. True to the company’s founding mission, Yuhan focuses its R&D efforts on developing the kinds of products people need most. By developing therapies for treating inflammatory, autoimmune, oncologic and metabolic diseases, Yuhan has significantly advanced the science and understanding of these prevalent disease processes. This rich body of knowledge and wealth of experience positions Yuhan on the cutting edge for developing unique, innovative, finished products and to partnering successfully with other developers. Yuhan: A Global Best Partner Equipped with state-of-the-art research capabilities and manufacturing facilities compliant with the United States Food and Drug Administration (FDA) current Good Manufacturing Practices (cGMP) regulations, Yuhan is growing into a global pharmaceutical company that offers one-stop custom synthesis services from R&D to commercial production of active pharmaceutical products (APIs) and intermediates. Yuhan has undergone successful audits by many international regulatory agencies such as the FDA, the European Medicines Agency and the European Directorate for the Quality of Medicines (EMEA/EDQM), Australia’s Therapeutic Goods Amdinistration (TGA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). Yuhan has successfully provided high-quality APIs and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets. Yuhan continues to expand its overseas markets by supplying finished products. The process began in 2010 with the out-licensing to China of Yuhan’s Revanex, the world’s first acid pump antagonist (APA). Revanex is now supplied world-wide to India, Southeast Asia, South America and the Middle East, improving the health and quality of life for individuals suffering from peptic ulcers and gastritis-related mucosal injury.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
74, Noryangjin-ro, Daebang-dong, Dongjak-gu, SEOUL
Telephone
Telephone
+82-2-828-0181
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI South East Asia

Not Confirmed

envelop Contact Supplier

CPhI South East Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets
With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 1241

https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

Radio Compass
06 May 2025

VLOG #PharmaReel

[Sponsored by another company]
This PharmaReel showcases Allsino Pharmaceutical, a company that provides GMP-certified RSMs and APIs to global pharma companies, specializing in peptides, oligonucleotides, and small molecule CDMO services. Allsino has a presence in the US, EU, China and Japan.

Impressions: 1278

read-more

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025
The pharmaceutical industry has witnessed a wave of mergers, acquisitions, and strategic partnerships so far in the first half (H1) of 2025, with deal values exceeding US$ 170 billion.PharmaCompass’ data shows oncology alone accounted for nearly US$ 47 billion in deal value, followed by US$ 18 billion each in immunology and psychiatry, US$ 17 billion in nutrition/weight loss and US$ 7 billion in neurology.Pharma majors such as Johnson & Johnson and Bristol Myers Squibb led with two deals worth over US$ 10 billion each. Sanofi executed a series of deals in the immunology and neuro-inflammation space. And Eli Lilly stood out for its aggressive dealmaking, which spanned oncology, pain, RNA therapies, and AI-driven oligonucleotides. In all, it signed seven deals worth over US$ 1 billion each. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available)H1 records several mega deals as J&J buys Intra-Cellular, BMS ties up with BioNTech, Sanofi acquires BlueprintJohnson & Johnson dominated headlines with its US$ 14.6 billion acquisition of Intra-Cellular Therapies in January 2025. This marks the largest biopharma deal since Novo Nordisk’s US$ 16.5 billion acquisition of Catalent in February 2024. This acquisition positions J&J as a formidable player in the neuroscience space. Bristol Myers Squibb entered into a US$ 11.1 billion partnership with BioNTech. The deal structure — US$ 3.5 billion in unconditional payments and up to US$ 7.6 billion in milestone payments — demonstrates BMS’ confidence in BNT327, a next-generation bispecific antibody in phase 3 trials for treating extensive stage small cell lung cancer and non-small cell lung cancer.Sanofi acquired Blueprint Medicines for US$ 9.5 billion in order to enhance its rare disease portfolio. The French drugmaker is also creating a comprehensive immunology portfolio. The company signed a US$ 1.9 billion deal for Dren Bio’s DR-0201 bispecific antibody for autoimmune diseases. Sanofi also acquired Vigil Neuroscience for US$ 470 million for its phase 2-ready Alzheimer’s disease candidate. Additionally, the drugmaker secured a US$ 1.84 billion global license agreement with Earendil Labs for two next-generation bispecific antibodies.Pfizer’s US$ 6.05 billion partnership with 3SBio provides it global licensing rights (excluding China) for SSGJ-707, a bispecific antibody currently undergoing multiple clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Obesity gold rush sees Roche, AbbVie, Sciwind ink deals; Novo pledges over US$ 5 bn across three dealsThe obesity therapeutics market has triggered intense competition among pharmaceutical giants. Roche’s US$ 5.3 billion partnership with Zealand Pharma is focused on petrelintide, an amylin analog designed to preserve lean mass better than existing GLP-1-based treatments. The collaboration combines petrelintide with Roche’s dual GLP-1/GIP receptor agonist CT-388, creating a differentiated obesity treatment.Market leader Novo Nordisk has promised over US$ 5 billion across three major obesity deals in 2025. The US$ 2.2 billion Septerna collaboration targets oral small molecule medicines for obesity and cardiometabolic diseases.Novo signed a separate US$ 2 billion agreement with China’s United Biotechnology for UBT251, a triple agonist for GLP-1, GIP, and glucagon receptors in phase 2 clinical development for obesity, type 2 diabetes, and other diseases. The company’s third major deal, a US$ 1 billion partnership with Lexicon Pharmaceuticals, provides it access to LX9851, a molecule in preclinical development for obesity and associated metabolic disorders.Sciwind Biosciences secured a US$ 2.5 billion global licensing and collaboration agreement with Verdiva Bio Limited for the global development and commercialization of a portfolio of metabolic diseases therapies. AbbVie entered the amylin arena through its US$ 2.2 billion Gubra partnership for GUB014295, a candidate in phase 1 trials for treating obesity. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Molecular glue degraders draw investments; Lilly signs seven deals over US$ 1 billion eachMolecular glue degraders have emerged as a transformative therapeutic modality, attracting significant investment across multiple partnerships. AbbVie’s US$ 1.64 billion collaboration with Neomorph leverages the biotech’s leading molecular glue discovery platform for oncology and immunology applications.Genentech’s potential US$ 2.1 billion partnership with Orionis Biosciences focuses on small-molecule monovalent glue medicines for novel and challenging oncology targets. This is the second partnership between the two companies, following their initial 2023 collaboration.Eli Lilly has collaborated with Magnet Biomedicine, utilizing Magnet’s TrueGlue discovery platform for oncology applications. The deal could be worth up to US$ 1.3 billion.Eli Lilly has emerged as one of 2025’s most active dealmakers, with approximately seven deals exceeding US$ 1 billion each. The company’s US$ 2.5 billion Scorpion Therapeutics acquisition provides access to STX-478, an experimental oral therapy in early-stage trials for breast cancer and advanced solid tumors, potentially addressing 30 to 40 percent of hormone-positive breast cancer patients.On June 17, Lilly announced the acquisition of gene-editing startup Verve Therapeutics for US$ 1.3 billion. Lilly’s US$ 1 billion SiteOne acquisition announced in May brings STC-004, a phase 2-ready non-opioid chronic pain treatment to its pipeline. Other partnerships announced by Lilly include a US$ 1.4 billion capsid licensing deal with Sangamo for central nervous system disease genomic medicines and a US$ 1.3 billion collaboration with South Korean company Rznomics for RNA-based hearing loss treatments. Lilly has also strengthened its oligonucleotide pipeline through a potential US$ 1 billion collaboration with Creyon Bio for AI-designed oligonucleotide therapies targeting RNA. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Merck KGaA acquires SpringWorks for US$ 3.9 bn; Novartis buys out Anthos for US$ 3.1 bnAstraZeneca signed a US$ 5.3 billion AI-led research agreement with China’s CSPC Pharmaceuticals Group to advance the discovery of novel oral candidates for immunological diseases. Merck KGaA acquired SpringWorks for US$ 3.9 billion in April, which gave it access to two FDA-approved therapies — Ogsiveo (nirogacestat), the first and only approved therapy for adult patients with progressing desmoid tumors requiring systemic treatment, and Gomekli (mirdametinib), the first and only FDA-approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.Novartis’ US$ 3.1 billion Anthos Therapeutics acquisition centered around abelacimab, a potential first-in-class monoclonal antibody currently in three phase 3 studies for stroke and systemic embolism prevention in atrial fibrillation patients.GSK’s US$ 2 billion acquisition of Boston Pharmaceuticals’ efimosfermin targets steatotic liver disease (fatty liver disease). The medicine is also in clinical development for MASH treatment. GSK’s second major deal involved the US$ 1.15 billion acquisition of US biotech IDRx, strengthening its gastrointestinal cancer portfolio.The pharma industry also drew some private equity interest as Bain Capital acquired Japan’s Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group for US$ 3.3 billion. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Our viewDespite an uncertain geopolitical environment, the year has seen a surge in M&As and dealmaking in the first half of 2025. However, a sizable chunk of the acquisitions were bolt-on transactions, indicating that companies are not ready to take on risks, and are buying out smaller players who strategically fit into their operations. Going forward, there are indications that M&A activity will stay strong throughout 2025. 

Impressions: 2792

https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025

#PharmaFlow by PHARMACOMPASS
19 Jun 2025

NEWS #PharmaBuzz

read-more
read-more
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda

31 May 2023

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/yuhan-makes-325m-cancer-bet-challenge-boehringer-takeda

Nick Paul Taylor FIERCE BIOTECH
31 May 2023
Hanmi, LG Chem, Yuhan race to develop new obesity drug
Hanmi, LG Chem, Yuhan race to develop new obesity drug

23 May 2022

// Kim Chan-hyuk KOREABIOMED

http://www.koreabiomed.com/news/articleView.html?idxno=13737

Kim Chan-hyuk KOREABIOMED
23 May 2022

https://www.koreabiomed.com/news/articleView.html?idxno=12577

Shim Hyun-tai KOREABIOMED
17 Nov 2021

http://www.koreaherald.com/view.php?ud=20201123000807#:~:text=Yuhan%20gets%20%2465m%20from%20Janssen%20for%20lazertinib%20milestone%20achievement&text=Yuhan%20Corp.%20made%20a%20regulatory,milestone%20payment%20from%20Janssen%20Biotech.

KOREAHERALD
23 Nov 2020

http://www.koreaherald.com/view.php?ud=20200701000846

By Lim Jeong-yeo KOREAHERALD
01 Jul 2020

https://endpts.com/after-inking-a-string-of-pipeline-deals-boehringer-ingelheim-is-doing-a-makeover-of-the-top-executive-team/

John Carroll ENDPTS
26 Aug 2019

01

Piperacillin Sodium

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Piperacillin Sodium

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS arrow-down JDMF EU-WC NDC arrow-down KDMF arrow-down VMF Others AUDIT
blank

02

Levofloxacin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Levofloxacin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF Inactive-api CEP/COS JDMF arrow-down EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

03

Ribavirin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Ribavirin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF arrow-down CEP/COS Inactive-api JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Cilostazol

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Cilostazol

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

05

Ketoprofen

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Ketoprofen

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

06

Levofloxacin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Levofloxacin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

07

Rosuvastatin Calcium

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Rosuvastatin Calcium

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

08

Rosuvastatin Calcium

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Rosuvastatin Calcium

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

09

Voglibose

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Voglibose

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

10

Cefaclor

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Specialty & Agro Chemical
Not Confirmed
arrow

Cefaclor

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Specialty & Agro Chemical
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

The Ministry of Food and Drug Safety announced its approval for the third-generation non-small cell lung cancer treatment, Leclaza. Leclaza is a swallowable tablet that can be taken at a fixed time every day, regardless of meals.


Lead Product(s): Lazertinib

Therapeutic Area: Oncology Brand Name: Leclaza

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 18, 2021

blank

01

Yuhan Corporation

South Korea
arrow
Specialty & Agro Chemical
Not Confirmed

Yuhan Corporation

South Korea
arrow
Specialty & Agro Chemical
Not Confirmed

Details : The Ministry of Food and Drug Safety announced its approval for the third-generation non-small cell lung cancer treatment, Leclaza. Leclaza is a swallowable tablet that can be taken at a fixed time every day, regardless of meals.

Product Name : Leclaza

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 18, 2021

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Yuhan Corporation and get a quotation

Yuhan Corporation is a supplier offers 26 products (APIs, Excipients or Intermediates).

Find a price of Piperacillin Sodium bulk with DMF, CEP offered by Yuhan Corporation

Find a price of Levofloxacin bulk with JDMF offered by Yuhan Corporation

Find a price of Ribavirin bulk with DMF offered by Yuhan Corporation

Find a price of Cilostazol bulk with JDMF offered by Yuhan Corporation

Find a price of Ketoprofen bulk with JDMF offered by Yuhan Corporation

Find a price of Rosuvastatin Calcium bulk with JDMF offered by Yuhan Corporation

Find a price of Voglibose bulk with JDMF offered by Yuhan Corporation

Find a price of Cefaclor bulk offered by Yuhan Corporation

Find a price of Zidovudine bulk offered by Yuhan Corporation

Find a price of FACILITY AND OPERATING PROCEDURES IN ANSANSHI, KYONGGI-DO, SOUTH KOREA bulk offered by Yuhan Corporation

Find a price of Atorvastatin bulk offered by Yuhan Corporation

Find a price of Cobicistat bulk offered by Yuhan Corporation

Find a price of Elvitegravir bulk offered by Yuhan Corporation

Find a price of Emtricitabine bulk offered by Yuhan Corporation

Find a price of Ezetimibe bulk offered by Yuhan Corporation

Find a price of Lazertinib bulk offered by Yuhan Corporation

Find a price of Ledipasvir bulk offered by Yuhan Corporation

Find a price of Lenacapavir bulk offered by Yuhan Corporation

Find a price of Revaprazan bulk offered by Yuhan Corporation

Find a price of Sarpogrelate Hydrochloride bulk offered by Yuhan Corporation

Find a price of Tazobactam Sodium bulk offered by Yuhan Corporation

Find a price of Telmisartan bulk offered by Yuhan Corporation

Find a price of Velpatasvir bulk offered by Yuhan Corporation

Find a price of Voxilaprevir bulk offered by Yuhan Corporation

Find a price of Silicon dioxide adsorption corbicistat bulk offered by Yuhan Corporation

Find a price of Belpatasvir bulk offered by Yuhan Corporation

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty